Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.
Kednapa ThavornEmily Rose ThompsonSrishti KumarAliisa HeiskanenAnubhav AgarwalHarold AtkinsRisa ShorrTerry HawryshKelvin Kar-Wing ChanJustin PresseauDaniel A OllendorfIan D GrahamJeremy M GrimshawManoj Mathew LaluSurapon NochaiwongDean A FergussonBrian HuttonDoug CoyleNatasha KekrePublished in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2024)
CAR-T therapies were more expensive and generated more QALYs than comparators, but their cost-effectiveness was uncertain and dependent on patient population, cancer type, and model assumptions. This highlights the need for more nuanced economic evaluations and continued research to better understand the value of CAR-T therapies in diverse patient populations.